Antidepressants (eBook, PDF)
From Biogenic Amines to New Mechanisms of Action
Redaktion: Macaluso, Matthew; Preskorn, Sheldon H.
113,95 €
113,95 €
inkl. MwSt.
Sofort per Download lieferbar
57 °P sammeln
113,95 €
Als Download kaufen
113,95 €
inkl. MwSt.
Sofort per Download lieferbar
57 °P sammeln
Jetzt verschenken
Alle Infos zum eBook verschenken
113,95 €
inkl. MwSt.
Sofort per Download lieferbar
Alle Infos zum eBook verschenken
57 °P sammeln
Antidepressants (eBook, PDF)
From Biogenic Amines to New Mechanisms of Action
Redaktion: Macaluso, Matthew; Preskorn, Sheldon H.
- Format: PDF
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
This volume reviews the known neurobiology of depression and combines classic data on antidepressant treatments with modern theory on the physiology of depression. It also discusses novel mechanism of action drugs.
- Geräte: PC
- ohne Kopierschutz
- eBook Hilfe
- Größe: 7.43MB
Andere Kunden interessierten sich auch für
- The Neuropharmacology of Alcohol (eBook, PDF)169,95 €
- Nicotine Psychopharmacology (eBook, PDF)233,95 €
- Endocannabinoids (eBook, PDF)258,95 €
- -29%11Clinical Pharmacology of Sleep (eBook, PDF)113,95 €
- Sylvia WagnerArzneimittelversuche an Heimkindern zwischen 1949 und 1975 (eBook, PDF)27,99 €
- Novel Antischizophrenia Treatments (eBook, PDF)314,95 €
- Patrick SchubertNeuroenhancement revisited: Wie Antidepressiva die alltägliche Leistungsfähigkeit erhalten und verbessern (eBook, PDF)34,99 €
-
-
-
This volume reviews the known neurobiology of depression and combines classic data on antidepressant treatments with modern theory on the physiology of depression. It also discusses novel mechanism of action drugs.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Springer Nature Switzerland
- Seitenzahl: 442
- Erscheinungstermin: 31. Mai 2019
- Englisch
- ISBN-13: 9783030109493
- Artikelnr.: 56897693
- Verlag: Springer Nature Switzerland
- Seitenzahl: 442
- Erscheinungstermin: 31. Mai 2019
- Englisch
- ISBN-13: 9783030109493
- Artikelnr.: 56897693
- Herstellerkennzeichnung Die Herstellerinformationen sind derzeit nicht verfügbar.
Part 1: Overview and General Principles.- 1. Impact, Diagnosis, Phenomenology, and Biology.- Part 2: The Past - from antiquity to 1970 including TCAs and MAOIs.- 2. Tricyclic Antidepressants and Monoamine Oxidase Inhibitors: Are They Too Old for a New Look?.- Part 3: The Present- 1970 to 2016.- 3. Clinical Implications of the STAR D Trial.- 4. Pharmacogenomics and Biomarkers of Depression.- 5. Therapeutic Drug Monitoring of Antidepressants.- 6. Selective Serotonin Reuptake Inhibitors.- 7. Serotonin and Norepinephrine Reuptake Inhibitors.- 8. Neurostimulation Therapies.- 9. Current Role of Herbal and Natural Preparations.- Part 4: The future.- 10. Role of Inflammation in Depression and Treatment Implications.- 11. NMDA Antagonists for Treatment-Resistant Depression.- 12. Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development.- 13. Other Antidepressants.- Part 5: Use of Antidepressants in Special Populations.- 14. Use of Antidepressants in Patients with Co-occurring Depression and Substance Use Disorders.- 15. Treatment of Depression in Women.- 16. Management of Late-Life Depression.- 17. The Use of Antidepressants in Bipolar Depression.
Part 1: Overview and General Principles.- 1. Impact, Diagnosis, Phenomenology, and Biology.- Part 2: The Past - from antiquity to 1970 including TCAs and MAOIs.- 2. Tricyclic Antidepressants and Monoamine Oxidase Inhibitors: Are They Too Old for a New Look?.- Part 3: The Present- 1970 to 2016.- 3. Clinical Implications of the STAR*D Trial.- 4. Pharmacogenomics and Biomarkers of Depression.- 5. Therapeutic Drug Monitoring of Antidepressants.- 6. Selective Serotonin Reuptake Inhibitors.- 7. Serotonin and Norepinephrine Reuptake Inhibitors.- 8. Neurostimulation Therapies.- 9. Current Role of Herbal and Natural Preparations.- Part 4: The future.- 10. Role of Inflammation in Depression and Treatment Implications.- 11. NMDA Antagonists for Treatment-Resistant Depression.- 12. Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development.- 13. Other Antidepressants.- Part 5: Use of Antidepressants in Special Populations.- 14. Use of Antidepressants in Patients with Co-occurring Depression and Substance Use Disorders.- 15. Treatment of Depression in Women.- 16. Management of Late-Life Depression.- 17. The Use of Antidepressants in Bipolar Depression.
Part 1: Overview and General Principles.- 1. Impact, Diagnosis, Phenomenology, and Biology.- Part 2: The Past - from antiquity to 1970 including TCAs and MAOIs.- 2. Tricyclic Antidepressants and Monoamine Oxidase Inhibitors: Are They Too Old for a New Look?.- Part 3: The Present- 1970 to 2016.- 3. Clinical Implications of the STAR D Trial.- 4. Pharmacogenomics and Biomarkers of Depression.- 5. Therapeutic Drug Monitoring of Antidepressants.- 6. Selective Serotonin Reuptake Inhibitors.- 7. Serotonin and Norepinephrine Reuptake Inhibitors.- 8. Neurostimulation Therapies.- 9. Current Role of Herbal and Natural Preparations.- Part 4: The future.- 10. Role of Inflammation in Depression and Treatment Implications.- 11. NMDA Antagonists for Treatment-Resistant Depression.- 12. Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development.- 13. Other Antidepressants.- Part 5: Use of Antidepressants in Special Populations.- 14. Use of Antidepressants in Patients with Co-occurring Depression and Substance Use Disorders.- 15. Treatment of Depression in Women.- 16. Management of Late-Life Depression.- 17. The Use of Antidepressants in Bipolar Depression.
Part 1: Overview and General Principles.- 1. Impact, Diagnosis, Phenomenology, and Biology.- Part 2: The Past - from antiquity to 1970 including TCAs and MAOIs.- 2. Tricyclic Antidepressants and Monoamine Oxidase Inhibitors: Are They Too Old for a New Look?.- Part 3: The Present- 1970 to 2016.- 3. Clinical Implications of the STAR*D Trial.- 4. Pharmacogenomics and Biomarkers of Depression.- 5. Therapeutic Drug Monitoring of Antidepressants.- 6. Selective Serotonin Reuptake Inhibitors.- 7. Serotonin and Norepinephrine Reuptake Inhibitors.- 8. Neurostimulation Therapies.- 9. Current Role of Herbal and Natural Preparations.- Part 4: The future.- 10. Role of Inflammation in Depression and Treatment Implications.- 11. NMDA Antagonists for Treatment-Resistant Depression.- 12. Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development.- 13. Other Antidepressants.- Part 5: Use of Antidepressants in Special Populations.- 14. Use of Antidepressants in Patients with Co-occurring Depression and Substance Use Disorders.- 15. Treatment of Depression in Women.- 16. Management of Late-Life Depression.- 17. The Use of Antidepressants in Bipolar Depression.